# Time to consider doxycycline in the standard treatment of lymphatic filariasis? Emerging evidence on use of doxycycline as an adjunct to hygiene protocols

**Authors:** Mian Zahid Jan Kakakhel, Shree Rath, Maheen Sheraz, Diya Rathi, Raheel Ahmed

PMC · DOI: 10.1186/s41182-025-00726-4 · Tropical Medicine and Health · 2025-03-24

## TL;DR

This paper discusses the potential of adding doxycycline to hygiene protocols for treating lymphatic filariasis in tropical regions.

## Contribution

The paper presents emerging evidence supporting doxycycline as an effective adjunct in treating lymphatic filariasis.

## Key findings

- Doxycycline shows promise as an add-on drug in improving patient outcomes.
- Trials suggest doxycycline can be integrated into national elimination strategies.
- Combining doxycycline with hygiene protocols is practical in low-resource settings.

## Abstract

With lymphatic filariasis being a rampant condition in tropical countries, multiple treatment modalities are being explored for their efficacy and practicability of use in low resource settings. Doxycycline, a commonly available drug across the world, has been proposed to improve patient status in those suffering with lymphatic filariasis. In conjunct with hygiene protocols, emerging trials have highlighted the success of doxycycline as an add-on drug. In this letter, we highlight the major findings in recent trials, and the scope of integrating doxycycline into national elimination strategies against filariasis.

## Linked entities

- **Chemicals:** doxycycline (PubChem CID 54671203)

## Full-text entities

- **Diseases:** filariasis (MESH:D005368), lymphatic filariasis (MESH:D004605)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11931818/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC11931818/full.md

---
Source: https://tomesphere.com/paper/PMC11931818